83808-20-2Relevant academic research and scientific papers
IMIDAZOLE AND THIAZOLE DERIVATIVES AS ANTIVIRAL AGENTS
-
Page/Page column 15-16, (2010/02/15)
The present invention relates to compounds of the formula (I), wherein R1, R2, A, B, D, E, F, G and Ar are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections.
Inhibitors of Cyclic AMP Phosphodiesterase. 2. Structural Variations of N-Cyclohexyl-N-methyl-4-quinazolin-7-yl)oxy>butyramide (RS-82856)
Venuti, Michael C.,Jones, Gordon H.,Alvarez, Robert,Bruno, John J.
, p. 303 - 318 (2007/10/02)
A series of analogues of the cyclic AMP phosphodiesterase (PDE) inhibitor N-cyclohexyl-N-methyl-4-quinazolin-7-yl)oxy>butyramide (RS-82856, 1) was prepared by systematic variation of the side-chain substituent, length, position, connecting atom, and the parent heterocycle itself.The compounds were evaluated as inhibitors of cyclic AMP phosphodiesterase from both human platelets and rat or dog heart tissue and as inhibitors of ADP-induced platelet aggregation.Structure-activity correlations for the analogue series revealed significant limitations on the steric bulk of substituents on the 1,2,3,5-tetrahydroimidazoquinaazolin-2-one heterocycle and the position and length of the side-chain.As inhibitors of cyclic AMP phosphodiesterase (PDE), potency steadily increased with increasingly lipophilic side chains.In platelet aggregation inhibition studies, however, a maximum in activity was reached with 1, while more lipophilic compounds were significantly less active.Major changes in the heterocycle itself, represented by isomeric and other carbonyl variations, also decreased activity.The molecular features defined by this series of analogues of 1 correlate to a high degree with current understanding of thr chemical and topographical requirements of the active site of the FIII (type IV) form of cyclic AMP PDE.Selective inhibition of this enzyme has been proposed as the principal component of the positive inotropic action of a number of cardiotonic agents.
(2-Oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl) oxyalkylamides properties having phosphodiosterase inhibiting
-
, (2008/06/13)
Compounds according to the formula STR1 , its optical isomers, or a pharmaceutically acceptable salt thereof wherein: m and n are integers of 1 to 6; R1 is hydrogen or alkyl of 1 to 4 carbons; R2 is hydrogen or R1 and R2 are combined to form an oxo group; R3 is hydrogen, alkyl of 1 to 6 carbons, phenyl, benzyl, hydroxy lower alkyl and its aliphatic acylates of 1 to 6 carbon atoms or aryl acylates of 7 to 12 carbon atoms, carbamoyl alkyl, carboxyalkyl, alkoxycarbonylalkyl or α-amino acid side chains; R4 is hydrogen, alkyl of 1 to 6 carbons, benzyl, or hydroxy lower alkyl; R5 is hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms or cycloalkyl lower alkyl of 4 to 12 carbon atoms wherein the cycloalkyl ring is unsubstituted or substituted with a lower alkyl, lower alkoxy, --OH, --OCOR6, halo, --NH2, --N(R6)2, --NHCOR6, --COOH, or --COO(R6) group wherein R6 is lower alkyl; phenyl or phenyl lower alkyl wherein phenyl is unsubstituted or substituted with 1 or more lower alkyl, halo or lower alkoxy groups or an --NH2, --N(R6)2, --NHCOR6, --COOH, or --COOR6 group wherein R6 is lower alkyl; Y is hydrogen, alkyl of 1 to 4 carbon atoms, halo or lower alkoxy; and Z is --OR7 or --NR7 R8 wherein R7 and R8 are independently hydrogen or lower alkyl.
OXYDATION OF SECONDARY AMINES TO α-CYANOAMINES
Barton, Derek H. R.,Billion, Annick,Boivin, Jean
, p. 1229 - 1232 (2007/10/02)
The dehydrogenation of secondary amines with phenylseleninic anhydride or acid under mild conditions in the presence of either sodium cyanide or trimethylsilylcyanide gives good yields of α-cyanoamines.These compounds can be regarded as protected imines, or as a source of α-amino-acids.
